News | tctmd.com

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

Stent thrombosis, though rare, mostly occurred in the first 30 days, suggesting aspirin needs to stay early on in select cases.

By Todd Neale

November 20, 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

PCR London Valves 2019

Solid 2-Year Outcomes for Portico, With Paravalvular Leak Rare

Yet experts questioned the low PVL rate, as well as the valve’s potential propensity for subclinical leaflet thrombosis.

By Michael O'Riordan

November 20, 2019

Solid 2-Year Outcomes for Portico, With Paravalvular Leak Rare

PCR London Valves 2019

Signal of Impaired Sapien XT Durability in Midterm Follow-up

Sapien 3, on the other hand, is holding up just at well as surgical bioprostheses in midterm follow-up from PARTNER 2A.

By Michael O'Riordan

November 20, 2019

Signal of Impaired Sapien XT Durability in Midterm Follow-up

VICTORIA Trial of Vericiguat for Worsening HF Meets Primary Endpoint

Top-line results indicate that the investigational drug reduced the risk of CV death/heart failure hospitalization.

By Todd Neale

November 20, 2019

VICTORIA Trial of Vericiguat for Worsening HF Meets Primary Endpoint

Grief and CVD: Simple Regimen May Lower Risk

Bereavement poses unique stresses on the heart. Six weeks of low-dose metoprolol and aspirin may help prevent CV events.

By L.A. McKeown

November 19, 2019

Grief and CVD: Simple Regimen May Lower Risk

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

Two small studies, with two different targets, show effective and sustained triglyceride-lowering in healthy volunteers.

By Caitlin E. Cox

November 19, 2019

Early Data Favorable for New RNAi Therapies to Reduce Triglycerides

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Experts are encouraged by these results, suggesting that inclisiran may someday replace PCSK9 inhibitors in patients with FH.

By Yael L. Maxwell

November 19, 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

PCR London Valves 2019

Two Small Series Support Role for Cerebral Protection in TAVR

The RCT data don’t support routine use, but one doctor says the benefit makes intuitive sense, even if more studies are needed.

By Michael O'Riordan

November 18, 2019

Two Small Series Support Role for Cerebral Protection in TAVR

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

The findings might provide a mechanistic explanation for at least some of the CV event reduction seen in REDUCE-IT.

By Todd Neale

November 18, 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

The study was stopped early but still met its primary endpoint and helps fill an evidence gap in stroke.

By Shelley Wood

November 18, 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial